Departed
John Gandolfo
director
ODYY ·
Odyssey Health, Inc.
Effective October 5, 2023, John Gandolfo resigned as a director of Odyssey Health, Inc.
Ready 8-Ks
50
Latest filing
May 22, 2026, 7:07 PM ET
Top materiality
0.75
Event mix
debt ×21 · other_material ×21 · m_and_a ×5
Sentiment
12 pos · 3 neg · 35 neu
Executive change
recent →
Recent 8-K filings for ODYY
Highest-materiality recent filing
Odyssey Health closes asset sale of brain illness drug candidates to Oragenics for $1M cash and 8M preferred shares
- Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.
- Received $1M in cash plus 8M shares of convertible Series F Preferred Stock from Oragenics.
-
Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract
NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.
-
Odyssey Health closes exclusive global distribution deal for BreastCheck non-invasive breast test
Closed sub-license with NeuRX Health granting subsidiary Odyssey Medical Devices exclusive worldwide marketing and distribution rights for BreastCheck.
-
Odyssey Health secures up to $25M financing facility and 9-year service contract
Entered Maintenance Agreement with Mast Hill Fund; issued $2.262M convertible note at 10% interest due Nov 2026.
-
Odyssey Health signs exclusive worldwide sub-license for BreastCheck non-invasive breast test
Sub-license grants exclusive global marketing and distribution rights for BreastCheck, a 15-minute at-home test.
-
Odyssey Health closes $220K convertible note and warrant financing with Mast Hill Fund
Principal $220,000, one-year, 10% note convertible at 85% of 10-day VWAP; default rate 16%.
-
Odyssey Health enters $25M equity purchase agreement with Mast Hill Fund
Entered $25M equity purchase agreement with Mast Hill Fund; shares sold at 97% of VWAP discount.
-
Odyssey Health extends maturity dates on two promissory notes to July 31, 2025
Extended Jon Lutz promissory note maturity to July 31, 2025 (Amendment No. 3).
-
Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.
-
Odyssey Health shareholders approve asset sale to Oragenics for $1M cash + 8M shares
Stockholders voted 45,032,700 for, 382,191 against the asset sale to Oragenics.
-
Odyssey Health shareholders approve asset sale of neurological drug therapies to Oragenics
Approved asset purchase agreement of neurological drug therapies and technologies to Oragenics, Inc.
-
Odyssey Health sells neurological drug pipeline to Oragenics for $1M and 8M preferred shares
Oragenics to acquire Odyssey's assets including concussion drug ONP-002 and NPC candidate; cash payment of $1M and 8M Series F Preferred Shares.
-
Extended maturity on five promissory notes from directors/officers to Oct 31, 2023; conversion price $0.12/share.
-
Odyssey Health signs non-binding LOI to merge with Speranza Therapeutics in all-stock deal
Speranza's lead product ST Genesis is a wearable device for opioid withdrawal, FDA cleared, 93% response rate, targets $1.4B market.
-
Odyssey Health acquires option to purchase PRV-001 patents from Prevacus for 1M shares
Option to buy 100% of worldwide patents to PRV-001 and an Enantiomer from Prevacus.
-
Odyssey Health files patent for intranasal brain-drug device; Phase I study successful
Filed US/global patent for breath-propelled intranasal brain-drug delivery device (Nasal Device).
-
Odyssey Health completes Phase I trial for concussion drug PRV-002; drug safe and well-tolerated
Phase I SAD and MAD trial enrolled 40 healthy volunteers; drug was safe and well-tolerated with no severe adverse events.
-
Odyssey Health receives 8M shares back from shareholder; shares retired to treasury
Shareholder returned 8 million common stock shares to the company on September 15, 2022.
-
Shareholder returned 7,370,000 shares; received by transfer agent on July 27, 2022.
-
Odyssey Health closes second closing of private placement; gross proceeds $415,650
Second closing issued 1,781,358 Units at $0.35/Unit for gross proceeds of $415,650.20.
-
Odyssey Health reports positive initial Phase I results for concussion drug PRV-002
First group of 5 healthy subjects dosed with PRV-002 showed safety and tolerability; no serious adverse events.
-
Odyssey Health closes initial $1.0M private placement of 4.3M units at $0.35
First closing on April 14, 2022, issued 4,306,200 units at $0.35 each; each unit equals one share and one-half warrant.
Executive changes
Departed
Jeffrey Conroy
Director
ODYY ·
Odyssey Health, Inc.
Effective January 4, 2023, Jeffrey Conroy resigned as a director of Odyssey Health, Inc.
Appointed
Greg Gironda
Chief Operations Officer
ODYY ·
Odyssey Health, Inc.
On November 1, 2022, the Company and Mr. Gironda entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Operations Officer.
Appointed
Erik Emerson
Chief Commercial Officer
ODYY ·
Odyssey Health, Inc.
On November 1, 2022, the Company and Mr. Emerson entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Commercial Officer.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event debt